Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01061021 · ClinicalTrials.gov registry record · Phase 2
HIV Prevention Intervention for People Living With HIV/AIDS
A Phase 2 study of HIV Infections, sponsored by University of Connecticut.
- Completed
- Registry status
- Phase 2
- Development phase
- 490
- Enrollment target
- 1
- Study location
NCT01061021 is a Phase 2 study of HIV Infections that has completed, run by University of Connecticut. The registered enrollment target is 490 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01061021, a Phase 2 study of HIV Infections, has completed, sponsored by University of Connecticut.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 490 participants
- Enrollment target
- 1
- Study location
Study Summary
HIV prevention interventions are needed to assist people living with HIV/AIDS to adhere to their medications and not transmit the virus to others. This study is testing a behavioral intervention designed to address both medication adherence and risk reduction in people living with HIV/AIDS. It is hypothesized that the experimental behavioral intervention will show improved medication adherence and safer sexual behaviors compared to a comparison group.
Conditions Studied
Interventions
- BEHAVIORAL In The Mix
- BEHAVIORAL Information Support Group
Study Locations (1)
Georgia
- Southeast HIV/AIDS Research and Evaluation Project - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01061021
The ClinicalTrials.gov registry entry for NCT01061021 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (10% higher). The listed sponsor is University of Connecticut, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which In The Mix is the first listed.
NCT01061021 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT01061021 about?
NCT01061021 is a clinical study titled "HIV Prevention Intervention for People Living With HIV/AIDS". HIV prevention interventions are needed to assist people living with HIV/AIDS to adhere to their medications and not transmit the virus to others. This study is testing a behavioral intervention designed to address both medication adherence and risk reduction in people living with HIV/AIDS. It is hy...
What is the current status of trial NCT01061021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 490 participants. The study started on 2005-03. Estimated completion is 2010-08.
What conditions does trial NCT01061021 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT01061021?
The interventions under investigation include: In The Mix (BEHAVIORAL), Information Support Group (BEHAVIORAL).
Who is sponsoring clinical trial NCT01061021?
This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01061021 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.